FR2480604A1 - Fractions nouvelles extraites de bacteries aerobies, douees de proprietes antitumorales, antibacteriennes et inductrices d'interferon et leur procede de preparation - Google Patents
Fractions nouvelles extraites de bacteries aerobies, douees de proprietes antitumorales, antibacteriennes et inductrices d'interferon et leur procede de preparation Download PDFInfo
- Publication number
- FR2480604A1 FR2480604A1 FR8008976A FR8008976A FR2480604A1 FR 2480604 A1 FR2480604 A1 FR 2480604A1 FR 8008976 A FR8008976 A FR 8008976A FR 8008976 A FR8008976 A FR 8008976A FR 2480604 A1 FR2480604 A1 FR 2480604A1
- Authority
- FR
- France
- Prior art keywords
- sep
- fraction
- interferon
- adjuvant
- corynebacterium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000003308 immunostimulating effect Effects 0.000 title claims abstract description 30
- 239000002671 adjuvant Substances 0.000 title claims abstract description 27
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 22
- 229960001438 immunostimulant agent Drugs 0.000 title claims abstract description 10
- 239000003022 immunostimulating agent Substances 0.000 title claims abstract description 10
- 102000014150 Interferons Human genes 0.000 title claims description 41
- 108010050904 Interferons Proteins 0.000 title claims description 41
- 229940079322 interferon Drugs 0.000 title claims description 41
- 241000186216 Corynebacterium Species 0.000 title claims description 25
- 230000001939 inductive effect Effects 0.000 title claims description 23
- 230000001580 bacterial effect Effects 0.000 title claims description 7
- 239000003814 drug Substances 0.000 title description 2
- 238000011282 treatment Methods 0.000 claims abstract description 15
- 241001148470 aerobic bacillus Species 0.000 claims abstract description 14
- 230000015961 delipidation Effects 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims description 15
- 230000008569 process Effects 0.000 claims description 8
- 244000005700 microbiome Species 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 4
- 239000012736 aqueous medium Substances 0.000 claims description 3
- 239000003599 detergent Substances 0.000 claims description 3
- 238000000227 grinding Methods 0.000 claims description 3
- 238000000265 homogenisation Methods 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 229960005486 vaccine Drugs 0.000 claims description 2
- 230000001988 toxicity Effects 0.000 claims 3
- 231100000419 toxicity Toxicity 0.000 claims 3
- 239000000470 constituent Substances 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 abstract description 5
- 210000004027 cell Anatomy 0.000 description 28
- 206010028980 Neoplasm Diseases 0.000 description 22
- 230000000694 effects Effects 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 238000007912 intraperitoneal administration Methods 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 11
- 238000012360 testing method Methods 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- 239000002799 interferon inducing agent Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 6
- 244000052616 bacterial pathogen Species 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 239000002158 endotoxin Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 241001464975 Cutibacterium granulosum Species 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 208000012322 Raynaud phenomenon Diseases 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 241000588832 Bordetella pertussis Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 241000600169 Maro Species 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 241000711975 Vesicular stomatitis virus Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000005748 tumor development Effects 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 108010023063 Bacto-peptone Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 241000218195 Lauraceae Species 0.000 description 1
- 235000017858 Laurus nobilis Nutrition 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 206010027458 Metastases to lung Diseases 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241000606701 Rickettsia Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical class [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 235000005212 Terminalia tomentosa Nutrition 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229940108605 cyclophosphamide injection Drugs 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 230000003861 general physiology Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229940090044 injection Drugs 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000003458 metachromatic effect Effects 0.000 description 1
- CEQFOVLGLXCDCX-WUKNDPDISA-N methyl red Chemical compound C1=CC(N(C)C)=CC=C1\N=N\C1=CC=CC=C1C(O)=O CEQFOVLGLXCDCX-WUKNDPDISA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229920000867 polyelectrolyte Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002714 polyornithine Polymers 0.000 description 1
- 108010055896 polyornithine Proteins 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- MPMFCABZENCRHV-UHFFFAOYSA-N tilorone Chemical compound C1=C(OCCN(CC)CC)C=C2C(=O)C3=CC(OCCN(CC)CC)=CC=C3C2=C1 MPMFCABZENCRHV-UHFFFAOYSA-N 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A61K2039/55594—Adjuvants of undefined constitution from bacteria
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8008976A FR2480604A1 (fr) | 1980-04-22 | 1980-04-22 | Fractions nouvelles extraites de bacteries aerobies, douees de proprietes antitumorales, antibacteriennes et inductrices d'interferon et leur procede de preparation |
| BE1/10201A BE888430A (fr) | 1980-04-22 | 1981-04-15 | Fractions nouvelles extraites de bacteries aerobies, douees de proprietes antitumorales, antibacteriennes et industrices d'interferon et leur procede de preparation, |
| US06/254,254 US4479935A (en) | 1980-04-22 | 1981-04-15 | Fractions extracted from aerobic bacteria, endowed with antitumoral, antibacterial and interferon inducing properties, and process for their preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8008976A FR2480604A1 (fr) | 1980-04-22 | 1980-04-22 | Fractions nouvelles extraites de bacteries aerobies, douees de proprietes antitumorales, antibacteriennes et inductrices d'interferon et leur procede de preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2480604A1 true FR2480604A1 (fr) | 1981-10-23 |
| FR2480604B1 FR2480604B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1984-02-17 |
Family
ID=9241205
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR8008976A Granted FR2480604A1 (fr) | 1980-04-22 | 1980-04-22 | Fractions nouvelles extraites de bacteries aerobies, douees de proprietes antitumorales, antibacteriennes et inductrices d'interferon et leur procede de preparation |
Country Status (2)
| Country | Link |
|---|---|
| BE (1) | BE888430A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) |
| FR (1) | FR2480604A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1987003202A1 (en) * | 1985-11-26 | 1987-06-04 | Sibar Srl | Fraction obtained from listeria monocytogenes having therapeutical activity, process for its preparation and pharmaceutical compositions containing it |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LU57091A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1968-10-15 | 1970-04-16 | ||
| FR2218888A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1973-02-23 | 1974-09-20 | Wellcome Found | |
| FR2268531A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1974-04-25 | 1975-11-21 | Anvar | |
| FR2269961A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1974-05-06 | 1975-12-05 | Anvar | |
| FR2283694A2 (fr) * | 1974-09-04 | 1976-04-02 | Anvar | Extraits hydrosolubles de mycobacteries de faible poids moleculaire, leur preparation et leur emploi |
| FR2374042A1 (fr) * | 1976-06-04 | 1978-07-13 | Merieux Inst | Nouveau medicament immunostimulant et son procede de preparation |
-
1980
- 1980-04-22 FR FR8008976A patent/FR2480604A1/fr active Granted
-
1981
- 1981-04-15 BE BE1/10201A patent/BE888430A/fr not_active IP Right Cessation
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LU57091A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1968-10-15 | 1970-04-16 | ||
| FR2020758A1 (en) * | 1968-10-15 | 1970-07-17 | Merieux Charles | Immunity stimulation against bacterial infec- - tions |
| FR2218888A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1973-02-23 | 1974-09-20 | Wellcome Found | |
| FR2268531A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1974-04-25 | 1975-11-21 | Anvar | |
| FR2269961A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1974-05-06 | 1975-12-05 | Anvar | |
| FR2283694A2 (fr) * | 1974-09-04 | 1976-04-02 | Anvar | Extraits hydrosolubles de mycobacteries de faible poids moleculaire, leur preparation et leur emploi |
| FR2374042A1 (fr) * | 1976-06-04 | 1978-07-13 | Merieux Inst | Nouveau medicament immunostimulant et son procede de preparation |
Non-Patent Citations (1)
| Title |
|---|
| CA1977 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1987003202A1 (en) * | 1985-11-26 | 1987-06-04 | Sibar Srl | Fraction obtained from listeria monocytogenes having therapeutical activity, process for its preparation and pharmaceutical compositions containing it |
| EP0230556A1 (en) * | 1985-11-26 | 1987-08-05 | SIBAR Srl | Fraction obtained from Listeria monocytogenes having therapeutical activity, process for its preparation and pharmaceutical compositions containing it |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2480604B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1984-02-17 |
| BE888430A (fr) | 1981-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3107568B2 (ja) | ブドウ膜炎の処置 | |
| US6814961B1 (en) | Method for enhancing stem cell trafficking | |
| EP0035429A1 (fr) | Complexe vaccinal contenant un antigène spécifique et vaccin le contenant | |
| FR2486400A1 (fr) | Medicaments a base de levures ou de leurs extraits insolubles | |
| CA1037028A (en) | Watersoluble extracts of corynebacteria, process for obtaining them and their use | |
| DE69213943T2 (de) | Kurzzeitige stimulierung von lymphozyten mit anti-cd3 antikörpern um ihre in vivo aktivität zu steigern | |
| Davis et al. | Spiroplasma floricola, a new species isolated from surfaces of flowers of the tulip tree, Liriodendron tulipifera L. | |
| CH641204A5 (fr) | Substance antitumorale obtenue par culture de mycelium. | |
| EP0037522B1 (fr) | Dérivés de l'entérotoxine thermostable de Escherichia Coli et leur préparation | |
| EP0015175A1 (fr) | Médicament constitué de Pichia ou d'extraits de Pichia | |
| EP0035937B1 (fr) | Utilisation de Hansenula ou d'extraits de Hansenula, comme médicament | |
| EP0071515B1 (fr) | Procédé d'obtention de polyosides capsulaires, polyosides capsulaires ainsi obtenus et leur application à la préparation de vaccins | |
| FR2523154A1 (fr) | Procede de preparation de proteoglycanes immunostimulants inducteurs d'interferon, proteoglycanes obtenus et medicaments les contenant | |
| CA2063721C (fr) | Medicament immunostimulant a base de glycopeptidolipides polaires de mycobacterium chelonae | |
| US4479935A (en) | Fractions extracted from aerobic bacteria, endowed with antitumoral, antibacterial and interferon inducing properties, and process for their preparation | |
| JPS58131917A (ja) | 抗動脈硬化剤 | |
| FR2480604A1 (fr) | Fractions nouvelles extraites de bacteries aerobies, douees de proprietes antitumorales, antibacteriennes et inductrices d'interferon et leur procede de preparation | |
| CA1117882A (fr) | Procede d'obtention d'un nouveau produit biologique et le produit en resultant | |
| JPS60146834A (ja) | 歯周炎抑制用抗体の製法及び同抗体を含有する歯周炎抑制用組成物 | |
| JPS5852227A (ja) | 淋菌からの免疫原性複合体 | |
| Smith | Effect of route of vaccination on the immune response of mice to a single dose of heat-killed Mycoplasma mycoides var. mycoides | |
| EP0139551A2 (fr) | Medicament immunomodulateur d'origine biologique et son procédé de préparation | |
| JPH04300898A (ja) | 新規糖タンパク複合体およびその製造方法 | |
| HU210826B (en) | Process for the preparation of an extracellular exopolymer and pharmaceutical compositions containing the same | |
| FR2536280A1 (fr) | Composition pharmaceutique et procede pour le traitement de tumeurs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ST | Notification of lapse |